ulmonary arterial hypertension (PAH) is a serious chronic disorder, similar to chronic kidney disease, which has varied causes and pathogenesis. PAH can potentially lead to right ventricular hypertrophy (RVH) and cardiovascular death related to RV failure. Among the types of PAH, idiopathic PAH has an especially poor prognosis and is difficult to manage clinically. Idiopathic PAH involves multiple factors, such as vasoconstriction, remodeling of the pulmonary vessels, and thrombosis, but it is unclear to what extent the sympathetic nervous activation plays a role in its development. Certainly, sympathetic nervous activity is reported to be increased in PAH; 1 however, it is unclear whether or not inhibition of sympathetic activity can prevent or reverse PAH. The benefits of inhibiting sympathetic nervous activation in PAH remain uncertain, although there have been several reports regarding the effects of α-and/or β-adrenergic receptor blockers, especially carvedilol, although it is not a pure α/ β-adrenergic receptor blocker. Arotinolol (Dainippon Sumitomo Pharma Co, Ltd, Osaka, Japan) is a nonselective α/ β-adrenergic receptor blocker lacking local anesthetic, membrane-stabilizing or intrinsic sympathomimetic properties, which means that arotinolol is a pure α/ β-adrenergic receptor blocker. 2,3
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Therefore, we investigated whether or not arotinolol, which differs from carvedilol with regard to actions such as an antioxidant or calcium-channel blocking effect, 4, 5 could prevent the development of PAH and/or RVH in a rat model of monocrotaline (MCT)-induced PAH.
Methods
The experimental procedures described in the present study were approved by the institutional Animal Care and Use Committee of Nippon Medical School. Six-week-old male Wistar rats (n=12) were used. MCT was dissolved in 1 N HCl, and the pH was adjusted to 7.4 with 1 N NaOH. Rats were injected subcutaneously with 2% MCT solution at a dose of 40 mg/kg. An intraperitoneal osmotic pump (Alzet Osmotic Pumps, Durect, Cupertino, CA, USA) containing either arotinolol (0.25 mg · kg -1 · day -1 , n=6) or 0.9% saline (n=6) was implanted randomly under anesthesia induced by intraperitoneal injection of sodium pentobarbital (30 mg/kg). A previous study showed intraperitoneal administration of arotinolol has almost the same effects as intravenous administration. 6 We did preliminary experiments to decide the dose of arotinolol required to reduce blood pressure (BP) within less than 10% from baseline, and it was 0.25 mg · kg -1 · day -1 , which we used in the present study. All rats were kept in a clean room and allowed water and food. Two weeks after administration of MCT, rats were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg/kg) and a 1.4Fr Millar catheter (Millar Instruments, Houston, TX, USA) was inserted into the RV and pulmonary artery via the right jugular vein and right atrium (RA). The catheter was connected to a pressure transducer (Nihon Koden Corporation, Tokyo, Japan) for measurement of pulmonary hemodynamics, heart rate (HR), arterial pressure (AP), pulmonary artery pressure (PAP), and right ventricular pressure (RVP). The aortic pressure and left ventricular pressure (LVP) were measured via the carotid artery. Enddiastole was defined as the initial point of positive dP/dt. After completing these measurements, the rats were killed and their hearts were removed immediately. Each heart was cut into 2 parts (right ventricular free wall [RV] and left 
Myocyte Preparation and Measurement
In several samples, cross-sectional specimens were immersed in 10% solution of formaldehyde. Masson-trichrome staining was performed to create representative images from both groups. To confirm precisely any differences in the degree of hypertrophy between the 2 groups, we examined the size of myocytes from the RV. After the physiological experiments, the hearts were rapidly removed and perfused with oxygenated (95% O2-5% CO2) calcium-free Tyrode's solution (mmol/L: NaCl 130, KCl 4.8, MgCl2 1.2, HEPES 10, glucose 5; pH=7.4) at 37°C and then with Enzyme 1 Solution (type 2 collagenase 33 mg, hyaluronidase 21 mg, Tyrode's solution 100 ml; Sigma Chemical Co, St Louis, MO, USA). Next, the RV was removed from each heart and minced with scissors in a separate vessel containing Enzyme 2 Solution (trypsin 20 mg and Enzyme 1 Solution 20 ml; Sigma). The tissue pieces were bubbled with 95% O2-5% CO2 for 10 min, filtered thorough a nylon mesh (300 μm), and washed with 20 ml of washing solution (Tyrode's solution 15 ml and experimental solution 15 ml). The tissue pieces were centrifuged at 550 rpm for 3 min at room temperature. The supernatant was discarded and the cells were resuspended on top of an albumin solution (bovine serum albumin 1.2 g and Tyrode's solution 20 ml). Isolated myocytes were placed in a cell chamber on the stage of an inverted microscope (Olympus, IX-70) that was continuously superfused at 37°C with the experimental solution (mmol/L: 130 NaCl, 4.8 KCl, 1.2 MgCl2, 5 glucose, 10 HEPES, 1 CaCl2). Cell length was measured using a SoftEdge video-based edge-detection system (IonOptix Corporation, Milton, MA, USA).
Statistical Analysis
All data are expressed as the mean ± standard error of mean. The effects of arotinolol were assessed by comparison with saline using Student's t-test. A P value <0.05 was considered to indicate statistical significance. All statistical analyses were performed with the Statistical Package for Social Sciences version 11.0 (SPSS Inc, Chicago, IL, USA).
Results
Hemodynamic Parameters (Table, Figures 1,2) The number of rats in each group was six. There were no significant differences in HR, systolic LVP, or mean AP between the 2 groups. LVEDP was higher in the control group, but the difference was not significant. Mean RAP and systolic RVP were significantly (P<0.05) higher in the control group compared with the arotinolol group. The differences in RVEDP between groups were similar to those for mean RAP. In the arotinolol group, systolic PAP, diastolic PAP, and mean PAP were 32±2, 18±2, and 21± 2 mmHg, respectively, which were significantly lower values than in the control group (73±8, 43±9, and 53± 9 mmHg, respectively).
Evaluation of Ventricular Hypertrophy (Figures 3,4)
Representative images of the cross-sectional specimens and histology are shown in Figure 3 . Body weight was not significantly different between the 2 groups. There were no significant differences in LV+S/BW between the groups, but the RV/BW ratio of the arotinolol group was significantly lower than that of the control group (0.58±0.01 vs 0.77±0.04 mg/g, P<0.01), suggesting that RVH was significantly prevented by arotinolol. Arotinolol also significantly prevented the increase in the maximum short-axis length of myocytes to 24.7±0.8 μm vs 30.9±1.1 μm in the control group (P<0.01), but not the maximum long-axis length 
Discussion
The present study demonstrated that PAH and RVH could be prevented by a pure α/ β-adrenergic receptor blocker, arotinolol, without a decrease in systemic BP, in a rat model of MCT-induced PAH, suggesting that the α/ β-adrenergic receptor blocker attenuated the progression of PAH and also prevented the development of RVH. In MCT-induced PAH, PA remodeling reportedly occurs, which also occurs in humans with primary PAH. Endothelial dysfunction leads to a chronic decrease in the production of vasodilators, such as nitric oxide and prostacyclin, together with overexpression of vasoconstrictors, such as ET-1 and thromboxanes, and also Rho-kinase activation. 8, 9 This imbalance induces vasoconstriction and smooth muscle cell activation, which leads to dysfunction, hyperplasia, and hypertrophy. In addition, there is inhibition of apoptosis, increased fibroblast proliferation, increased collagen deposition, and activation of pro-inflammatory cytokines and angiogenesis. These abnormalities cause increased vascular tone and promote vascular remodeling. 10 The role of the sympathetic nervous system in the process of PA remodeling is not well known. Inoue et al demonstrated that bunazosin hydrochloride, an α-adrenergic blocker, could attenuate the elevation of RV systolic pressure, but not RVH, in the same animal model. 11 Fujio et al demonstrated that carvedilol or propranolol, but not prazosin, inhibited the proliferation of arterial smooth muscle cells from patients with idiopathic PAH. 5 Kanemoto et al reported patients with primary PAH whose condition improved markedly when they received vasodilators combined with prazosin and isosorbide dinitrate. 12 Thus, an α/ β-adrenergic receptor blocker might improve PAH under appropriate conditions, but we do not know exactly which conditions are required for the prevention of PAH. The present study results suggest that early pharmacological intervention with an α/ β-adrenergic receptor blocker might prevent progression of PAH, although we did not directly examine endothelial function or histological abnormalities of the pulmonary arteries.
Several previous studies using the MCT-induced PAH model have shown downregulation of β1-adrenergic receptors and also a reduction of Gs protein-adenylyl cyclase activity in the RV during progression of MCT-induced RVH and RV failure, which suggests that increased sympathetic activity might be related to the progression of RVH. 13, 14 In patients with isolated RV failure because of primary PAH, Bristow et al found selective β1-receptor downregulation and decreased basal adenylyl cyclase activity. 15 Nervous stimulation of the ventricles and abnormalities of the adrenergic system are involved, because cardiac denervation prevents the progression of sympathetic abnormalities and cardiac dysfunction. 16 In the present study, we could not clarify the mechanism leading to the prevention of RVH, but it is possible that early inhibition of the progression of PAH might have delayed progression of RVH and inhibition of cardiac sympathetic activity may have also had a direct preventive effect.
Another possibility for the prevention of the progression of PAH could be the indirect antiplatelet activity of α/ β-adrenergic receptor blockers. Platelet activation increases the release of platelet-derived growth factor and serotonin into the circulation. Increased availability of thromboxane, fibrinopeptide A, and plasminogen activator inhibitor-1 creates a pro-coagulant state in the pulmonary circulation, after which vasoconstriction, cell proliferation, and thrombosis combine to cause deleterious pulmonary vascular remodeling. The β-adrenergic receptor blockers have an inhibitory effect on platelet function. 17 Therefore, the indirect antiplatelet action of β-adrenergic receptor blockers might be a mechanism, but this should be confirmed by further studies.
One more possibility for the prevention of PAH is direct inhibition of the effects of MCT by arotinolol. It is known that MCT is metabolized in the liver and changed into pyrrole derivatives, which are toxic and cause vascular endothelial and smooth cell proliferation, obliteration of arterioles in the lung and induce RV hypertrophy with increased RV pressure. 18 Therefore, it is possible that arotinolol can directly inhibit the effects of all pyrrole derivatives of MCT immediately after administration.
Study Limitations
The present study did not directly examine pulmonary arterial wall hypertrophy, but we expect that PA remodeling would have been reduced in the arotinolol-treated rats because of the significant prevention of PAH. The number of cardiac α-and β-adrenergic receptors differs between rats and humans, 19, 20 and such differences could have influenced the results of the present study. Therefore, we also need to examine the preventive effect of arotinolol in PAH patients. We examined only a 2-week treatment period in the present study. It is possible that arotinolol treatment delayed the onset of PAH rather than attenuated the disease. In the present study, the aim was to reveal hemodynamic changes during the development of PAH and RVH. It is reported that carvedilol improves survival rate in MCT-induced PAH rats. 21 Therefore, we need to perform further study to clarify the effect of arotinolol on the long-term outcome.
We performed the experiments under anesthesia with pentobarbital, which reportedly elicits autonomic functions in rats. 22 Therefore, our data would be influenced by pentobarbital. However, differences between the 2 groups would still be manifested even under these conditions and it is extremely difficult to measure in conscious rats all the parameters investigated in the present study.
In conclusion, the present study demonstrated that the pure α/ β-adrenergic receptor blocker, arotinolol, could prevent the progression of MCT-induced PAH and RVH in rats, suggesting that sympathetic nervous activation plays a role in the development of PAH.
